Patents Assigned to AstraZeneca
  • Bis-(Sulfonylamino) Derivatives in Therapy 066
    Publication number: 20090281138
    Abstract: The invention provides compounds of formula wherein R1, R3, L1, L2, G1, G2, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.
    Type: Application
    Filed: November 14, 2008
    Publication date: November 12, 2009
    Applicant: AstraZeneca AB
    Inventors: Johan Bylund, Marie E. Ek, Annika Kers, Gunnar Nordvall, Liselotte Ohberg, Jenny Viklund, Stefan Von Berg, Jorg Holenz, Katja Narhi, Daniel Sohn, Martin H. Johansson
  • A Method And A Kit For Diagnosing Type 2 Diabetes, Metabolic Syndrome, Sub Clinical Atherosclerosis, Myocardial Infarct, Stroke Or Clinical Manifestations Of Diabetes
    Publication number: 20090280501
    Abstract: A method and a kit for diagnosing or prognosing susceptibility to develop type 2 diabetes, the metabolic syndrome, sub clinical atherosclerosis, myocardial infarct, stroke or clinical manifestations of diabetes in a subject. The method comprises detecting and quantifying the amount of bound protein (s), (apoCIII, apoCI, apoA1 or apoE) on small dense low density lipoproteins (sdLDL) particles in a blood sample from said subject.
    Type: Application
    Filed: April 10, 2006
    Publication date: November 12, 2009
    Applicant: ASTRAZENECA AB
    Inventors: German Camejo, Pia Davidsson, Johannes Hulthe
  • Combination Product
    Publication number: 20090281083
    Abstract: There is provided a combination product comprising: (A) BH4, a functional derivative or biosynthetic precursor thereof, or a pharmaceutically-acceptable derivative of BH4 or its derivative or precursor; and (B) an inhibitor of the biosynthesis and/or vasopressor function of AII, or a pharmaceutically-acceptable derivative thereof, wherein each of components (A) and (B) is formulated in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier, as well as the use of such a combination product in the treatment of hypertension and/or conditions characterised by vascular dysfunction and/or lesions.
    Type: Application
    Filed: April 13, 2006
    Publication date: November 12, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Anders Ljunggren, Peter Morsing
  • Apparatus and Methods for Dispensing Items
    Publication number: 20090277921
    Abstract: An item dispenser and methods for dispensing the item. In some embodiments of the invention, the item dispenser may include a housing, an item carriage, and a movable support. The movable support may be indexed to position the item carriage at (1) a first position in which the item carriage is positioned to release only a first item; and (2) a second position in which the item carriage is positioned to release a second item. In some embodiments of the invention, the dispenser may include a housing, a pivotable cap and a snap fastener. The snap fastener may extend from the cap to the housing and engage the housing to lock the cap in the closed position. The cap may be opened by moving an interference block away from a snap fastener lever.
    Type: Application
    Filed: May 8, 2008
    Publication date: November 12, 2009
    Applicant: AstraZeneca AB
    Inventors: Karen Angelucci, Brian D. Johnson, Michael L. Forehand, Janice Jackson, Dave Trapani, Adele Gulfo, Kathy Monday, Dean Whitney, Peter K. Bates, Alan Mudd
  • Therapeutic compounds
    Patent number: 7615642
    Abstract: Compounds of formula I or pharmaceutically acceptable salts thereof: wherein R1, R2, R3 and R4 are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
    Type: Grant
    Filed: April 16, 2007
    Date of Patent: November 10, 2009
    Assignee: AstraZeneca AB
    Inventors: William Brown, Ziping Liu, Daniel Page, Zena Qadoumi, Sanjay Srivastava, Maxime Tremblay, Christopher Walpole, Zhong-yong Wei, Hua Yang
  • Hydrophilic urinary catheter having a water-containing sachet
    Patent number: 7615045
    Abstract: A wetting apparatus (110) for wetting a hydrophilic urinary catheter (103) comprises a wetting receptacle (101) which defines a wetting fluid receiving area (102) for receiving the hydrophilic urinary catheter and a hydrophilic urinary catheter wetting fluid container (106) having a discharge outlet (126) movable from a closed position to an open position on application of a predetermined condition thereto to enable the wetting fluid to be discharged from the wetting fluid container.
    Type: Grant
    Filed: June 15, 2006
    Date of Patent: November 10, 2009
    Assignee: AstraZeneca AB
    Inventors: Anette Israelsson, Agneta Pettersson, Jan Utas
  • Piperidine derivatives as modulators of chemokine receptor CCR5
    Patent number: 7615555
    Abstract: Compounds of formula (I): compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal).
    Type: Grant
    Filed: April 20, 2005
    Date of Patent: November 10, 2009
    Assignee: AstraZeneca AB
    Inventors: Alan Faull, Howard Tucker
  • Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
    Publication number: 20090275578
    Abstract: The present invention is directed to compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Application
    Filed: August 12, 2005
    Publication date: November 5, 2009
    Applicants: AstraZeneca AB, NPS PHARMACEUTICALS, INC
    Inventors: Joshua Clayton, Fupeng Ma, Bradford Van Wagenen, Radhakrishnan Ukkiramapandian, Ian Egle, James Empfield, Methvin Isaac, Abdelmalik Slassi, Gary Steelman, Rebecca Urbanek, Sally Walsh
  • NOVEL COMPOUNDS-300
    Publication number: 20090275574
    Abstract: Compounds of Formula I, or pharmaceutically acceptable salts thereof: wherein R1, R2, R3, R4, m, n, q, s, t, X, and Y are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
    Type: Application
    Filed: April 30, 2009
    Publication date: November 5, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Yun-Xing Cheng, Vijayaratnam Santhakumar, Miroslaw Jerzy Tomaszewski
  • SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS
    Publication number: 20090275570
    Abstract: The invention relates to novel compounds of Formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds possess CHK1 kinase inhibitory activity, PDK1 inhibitory activity and Pak kinase inhibitory activity and are accordingly useful in the treatment and/or prophylaxis of cancer.
    Type: Application
    Filed: April 5, 2006
    Publication date: November 5, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Kevin Daly, Nicola Heron, Alexander Hird, Stephanos Ioannidis, James Janetka, Paul Lyne, Jaime Scott, Dorin Toader, Melissa Vasbinder, Dingwei Yu, Yan Yu
  • Crystalline forms of the anti-cancer compound ZD1839
    Patent number: 7612077
    Abstract: The invention concerns certain crystalline solvates and hydrates of the compound of the Formula (I) which is known inter alia by way of the code number ZD1839. In particular, the invention concerns a first solvate that occurs in the presence of methanol which is designated as Form 2 ZD1839 MeOH solvate, a second solvate that occurs in the presence of dimethyl sulphoxide which is designated as Form 3 ZD1839 DMSO solvate and a trihydrate that occurs in the presence of water which is designated Form 5 ZD1839 trihydrate. The invention further concerns processes for the preparation of these solvates and the trihydrate and for their conversion back to the compound ZD1839, pharmaceutical compositions containing them and their use in the manufacture of medicaments for use the production of an anti-proliferative effect in a warm-blooded animal such as man.
    Type: Grant
    Filed: February 24, 2003
    Date of Patent: November 3, 2009
    Assignee: Astrazeneca AB
    Inventor: John Peter Gilday
  • antibodies binding to a C-terminal fragment of apoliopoprotein E
    Patent number: 7612179
    Abstract: A human antibody fragment, which antibody or fragment: (i) binds to a polypeptide having the amino acid sequence shown in SEQ ID NO: 1 of the C-terminal domain of Apolipoprotein E (ApoE-CTD) or the amino acid sequence of a part thereof; and (ii) binds to human plaques.
    Type: Grant
    Filed: November 26, 2004
    Date of Patent: November 3, 2009
    Assignees: Astrazeneca AB, Dyax Corporation
    Inventors: Christer Nordstedt, Tom Goldschmidt, Maria Henderikx, René Hoet, Henricus Hoogenboom, Simon Hufton, Christin V. Andersson, Johanna Lindquist, Dan Sunnemark, Sergy Leonov
  • Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias
    Publication number: 20090270383
    Abstract: There is provided compounds of formula (I), wherein R1, R2, R3, R4, R41 to R46, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
    Type: Application
    Filed: July 6, 2009
    Publication date: October 29, 2009
    Applicant: AstraZeneca AB
    Inventors: Annika Bjore, Peter Bonn, Ulrik Gran, Johan Kajanus, Christina Olsson, Fritiof Ponten
  • Compounds I
    Publication number: 20090270470
    Abstract: Compounds of formula I, wherein R1, Z, X, Y, M and R2 are as defined in the specification, pharmaceutically acceptable salts thereof, pharmaceutical composition containing the same, methods of using the same for therapeutic purposes and methods of making the same.
    Type: Application
    Filed: May 8, 2006
    Publication date: October 29, 2009
    Applicant: AstraZeneca AB
    Inventors: Catrin Jonasson, Hakan Molin, Berit Molin, Didier Rotticci
  • CHEMICAL COMPOUNDS
    Publication number: 20090270450
    Abstract: The invention relates to chemical compounds of formula (I): or pharmaceutically acceptable salts thereof which possess CSF-1R kinase inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.
    Type: Application
    Filed: May 5, 2009
    Publication date: October 29, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Leslie Dakin, Kevin Daly, David Del Valle, Thomas Gero, Claude Afona Ogoe, David Scott, Xiaolan Zheng
  • PYRIMIDINE DERIVATIVES
    Publication number: 20090270390
    Abstract: The invention concerns pyrimidine derivatives of Formula (I) wherein each of p, R1, R2, q, R3, r, R4, X1 and Q1 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in a method for producing an anti-proliferative effect in a warm blooded animal such as man.
    Type: Application
    Filed: September 12, 2007
    Publication date: October 29, 2009
    Applicant: AstraZeneca
    Inventors: Sam Butterworth, Edward Jolyon Griffen, Martin Pass
  • Alkylsulphonamide quinolines
    Patent number: 7608628
    Abstract: Compounds of Formula II wherein R1, A, R2, R3, R4, R5, R8, n, m and q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Grant
    Filed: December 11, 2006
    Date of Patent: October 27, 2009
    Assignee: AstraZeneca AB
    Inventors: Thomas R. Simpson, James Kang, Jeffrey S. Albert, Cristobal Alhambra, Gerald M. Koether, James Woods, Yan Li
  • PROCESS FOR THE PREPARATION OF PYRIMIDINE COMPOUNDS
    Publication number: 20090264654
    Abstract: A process for the preparation of a compound of Formula (1) and intermediates useful therein are provided. The process comprises reacting a compound of formula R1—CO—CH2-E with a compound of formula R2—CHX1X2 in the presence of a compound of formula R3R4N—C(?NH)NH2 and a catalyst, thereby to form a dihydropyrimidine; and oxidising the dihydropyrimidine to form the compound of Formula (I). R1 is H or an alkyl group; R2 is H, an alkyl or aryl group; R3 and R4 are each independently H, alkyl or aryl, or R3 and R4 are linked to form, together with the nitrogen to which they are attached to form a 5 to 7 membered heterocyclic ring; E is H, an unsubstituted alkyl group, an aryl group or an electron withdrawing group; and X1 and X2 are each independently leaving groups, or X1 and X2 together represent ?O.
    Type: Application
    Filed: March 16, 2009
    Publication date: October 22, 2009
    Applicant: AstraZeneca UK Limited
    Inventors: Lee NEWTON, Mark Bailey
  • HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES
    Publication number: 20090264336
    Abstract: Compounds of formula (I) wherein R1, HET-1 and HET-2 are as described in the specification, and their salts and pro-drugs, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of formula (I) are also described.
    Type: Application
    Filed: September 3, 2008
    Publication date: October 22, 2009
    Applicant: AstraZeneca AB
    Inventors: Darren MCKERRECHER, Kurt Gordon Pike, Michael James Waring
  • APC antibodies
    Patent number: RE40948
    Abstract: A human gene termed APC is disclosed. Methods and kits are provided for assessing mutations of the APC gene in human tissues and body samples. APC mutations are found in familial adenomatous polyposis patients as well as in sporadic colorectal cancer patients. APC is expressed in most normal tissues. These results suggest that APC is a tumor suppressor.
    Type: Grant
    Filed: October 24, 2001
    Date of Patent: October 27, 2009
    Assignees: The Johns Hopkins University, Astrazeneca United Kingdom, Ltd., Cancer Institute, Japanese, Foundation for Cancer Research, The University of Utah
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, Hans Albertsen, Rakesh Anand, Mary Carlson, Joanna Groden, Philip Hedge, Geoff Joslyn, Alexander Fred Markham, Yusuke Nakumura, Andrew Thliveris, Raymond White